Efficacy of baricitinib 4 mg in patients with moderate‐to‐severe atopic dermatitis previously treated with systemic therapy

• Главные авторы: Antonio Costanzo (Автор), Akio Tanaka (Автор), Tiago Torres (Автор), Bibiana Pérez‐García (Автор), Angelina Sontag (Автор), Yun‐Fei Chen (Автор), Fan Emily Yang (Автор), Jill Kolodsick (Автор), Hitoe Torisu‐Itakura (Автор), Najwa Somani (Автор)
• Формат: ‌
• Опубликовано: Wiley, 2023-09-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Abstract Background The Janus kinase (JAK)1/JAK2 inhibitor baricitinib in combination with topical corticosteroids (TCS) improved moderate‐to‐severe atopic dermatitis (AD) in the phase 3 BREEZE‐AD7 trial. Patients with previous systemic therapy may have more severe, treatment‐resistant disease. Obje...